(VIANEWS) – Celsius Holdings (CELH), BanColombia S.A. (CIB), Corcept Therapeutics Incorporated (CORT) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Celsius Holdings (CELH)
77.6% sales growth and 16.18% return on equity
Celsius Holdings, Inc. develops, processes, markets, distributes, and sells functional drinks and liquid supplements in the United States and internationally. The company offers various carbonated and non-carbonated functional energy drinks under the CELSIUS Originals name; dietary supplement in carbonated flavors, including apple jack'd, orangesicle, inferno punch, cherry lime, blueberry pomegranate, strawberry dragon fruit, tangerine grapefruit, and jackfruit under the CELSIUS HEAT name; and branched-chain amino acids functional energy drink that fuels muscle recovery under the CELSIUS BCCA+ENERGY name. It also provides CELSIUS On-the-Go, a powdered form of the active ingredients in functional energy drinks in individual On-The-Go packets and canisters; and sparkling grapefruit, cucumber lime, and orange pomegranate, as well as pineapple coconut, watermelon berry, and strawberries and cream non-carbonated functional energy drinks under the CELSIUS Sweetened name; and CELSIUS ready-to drink products. It distributes its products through direct-to-store delivery distributors and direct to retailers, include supermarkets, convenience stores, drug stores, nutritional stores, and mass merchants, as well as health clubs, spas, gyms, the military, and e-commerce websites. The company was formerly known as Vector Ventures, Inc. and changed its name to Celsius Holdings, Inc. in January 2007. Celsius Holdings, Inc. was founded in 2004 and is headquartered in Boca Raton, Florida.
Earnings Per Share
As for profitability, Celsius Holdings has a trailing twelve months EPS of $0.48.
PE Ratio
Celsius Holdings has a trailing twelve months price to earnings ratio of 121.79. Meaning, the purchaser of the share is investing $121.79 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.18%.
Volume
Today’s last reported volume for Celsius Holdings is 1778940 which is 62.32% below its average volume of 4721260.
Yearly Top and Bottom Value
Celsius Holdings’s stock is valued at $58.46 at 19:22 EST, way under its 52-week high of $68.95 and way higher than its 52-week low of $26.75.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 225% and 46.2%, respectively.
2. BanColombia S.A. (CIB)
57% sales growth and 16.94% return on equity
Bancolombia S. A. provides various banking products and services to individual and corporate customers in Colombia, Panama, Puerto Rico, El Salvador, Costa Rica, and Guatemala. The company operates through nine segments: Banking Colombia, Banking Panama, Banking El Salvador, Banking Guatemala, Trust, Investment Banking, Brokerage, International Banking, and All Other. It offers checking and savings accounts, fixed term deposits, and investment products; trade financing, loans funded by domestic development banks, working capital loans, credit cards, personal and vehicle loans, payroll loans, and overdrafts; financial support to real estate developers and mortgages for individuals and companies; and financial and operating leasing services. The company also provides hedging instruments, including futures, forwards, options, and swaps; and brokerage, investment advisory, and private banking services, including selling and distributing equities, futures, foreign currencies, fixed income securities, mutual funds, and structured products. In addition, it offers cash management services; foreign currency transaction services; life, auto, commercial, and homeowner's insurance products; and online and computer banking services. Further, the company provides investment banking services comprising project and acquisition finance, debt and equity capital markets, principal investments, M&A, restructurings, and structured financing; money market accounts, mutual and pension funds, private equity funds, payment trust, custody, and corporate trust; and digital banking platform, transportation, securities brokerage, maintenance and remodeling, advertising and marketing, and outsourcing services, as well as credit cards. As of December 31, 2020, it operated 1,057 branches; 18,631 banking correspondents; 535 PAMs; 215 kiosks in El Salvador and 137 in Colombia; and 6,124 automatic teller machines. Bancolombia S.A. was incorporated in 1945 and is headquartered in MedellÃn, Colombia.
Earnings Per Share
As for profitability, BanColombia S.A. has a trailing twelve months EPS of $6.63.
PE Ratio
BanColombia S.A. has a trailing twelve months price to earnings ratio of 4.76. Meaning, the purchaser of the share is investing $4.76 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.94%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Dec 27, 2023, the estimated forward annual dividend rate is 2.86 and the estimated forward annual dividend yield is 9.07%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 0.1%, now sitting on 20.69T for the twelve trailing months.
3. Corcept Therapeutics Incorporated (CORT)
20.5% sales growth and 19.55% return on equity
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Earnings Per Share
As for profitability, Corcept Therapeutics Incorporated has a trailing twelve months EPS of $0.8.
PE Ratio
Corcept Therapeutics Incorporated has a trailing twelve months price to earnings ratio of 27.41. Meaning, the purchaser of the share is investing $27.41 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.55%.
Moving Average
Corcept Therapeutics Incorporated’s value is way under its 50-day moving average of $26.66 and way under its 200-day moving average of $26.41.
Revenue Growth
Year-on-year quarterly revenue growth grew by 21.5%, now sitting on 450.03M for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Corcept Therapeutics Incorporated’s EBITDA is 77.55.
4. Martin Marietta Materials (MLM)
17.4% sales growth and 14.93% return on equity
Martin Marietta Materials, Inc., a natural resource-based building materials company, supplies aggregates and heavy-side building materials to the construction industry in the United States and internationally. It offers crushed stone, sand, and gravel products; ready mixed concrete and asphalt; paving products and services; and Portland and specialty cement for use in the infrastructure projects, and nonresidential and residential construction markets, as well as in the railroad, agricultural, utility, and environmental industries. The company also produces magnesia-based chemicals products; dolomitic lime primarily to customers for steel production and soil stabilization; and cement treated materials. Its chemical products are used in flame retardants, wastewater treatment, pulp and paper production, and other environmental applications. Martin Marietta Materials, Inc. was founded in 1939 and is headquartered in Raleigh, North Carolina.
Earnings Per Share
As for profitability, Martin Marietta Materials has a trailing twelve months EPS of $17.71.
PE Ratio
Martin Marietta Materials has a trailing twelve months price to earnings ratio of 29.7. Meaning, the purchaser of the share is investing $29.7 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.93%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Martin Marietta Materials’s EBITDA is 42.65.
Revenue Growth
Year-on-year quarterly revenue growth grew by 10.1%, now sitting on 6.22B for the twelve trailing months.
Volume
Today’s last reported volume for Martin Marietta Materials is 136166 which is 55.46% below its average volume of 305744.
Sales Growth
Martin Marietta Materials’s sales growth is 18.1% for the current quarter and 17.4% for the next.
5. Paysign (PAYS)
14% sales growth and 9.36% return on equity
PaySign, Inc. provides prepaid card products and processing services under the PaySign brand for corporate, consumer, and government applications. It offers various services, such as transaction processing, cardholder enrollment, value loading, cardholder account management, reporting, and customer service through PaySign, a card processing platform. The company also develops prepaid card programs for corporate incentive and rewards, including consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments, and pharmaceutical payment assistance; and payroll or general purpose reloadable cards, as well as gift or incentive cards. In addition, it offers Per Diem, Corporate Expense, and Business Travel Cards that allows businesses, and non–profits and government agencies the ability to control employee spending while reducing administration costs by eliminating the need for traditional expense reports. Further, the company provides payment claims processing and other administrative services; pharmacy-based voucher and copay, and medical claims and debit-based affordability programs; PaySign Premier, a demand deposit account debit card; and payment solution for source plasma collection centers, as well as customer service center and PaySign Communications Suite services. Its principal target markets for processing services comprise prepaid card issuers, retail and private-label issuers, small third-party processors, and small and mid-size financial institutions in the United States and Mexico. The company was formerly known as 3PEA International, Inc. and changed its name to PaySign, Inc. in April 2019. PaySign, Inc. was incorporated in 1995 and is headquartered in Henderson, Nevada.
Earnings Per Share
As for profitability, Paysign has a trailing twelve months EPS of $0.03.
PE Ratio
Paysign has a trailing twelve months price to earnings ratio of 107.67. Meaning, the purchaser of the share is investing $107.67 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.36%.
Volume
Today’s last reported volume for Paysign is 300378 which is 139.52% above its average volume of 125406.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Paysign’s EBITDA is 60.34.
6. EastGroup Properties (EGP)
13.3% sales growth and 9.26% return on equity
EastGroup Properties, Inc. (NYSE: EGP), an S&P MidCap 400 company, is a self-administered equity real estate investment trust focused on the development, acquisition and operation of industrial properties in major Sunbelt markets throughout the United States with an emphasis in the states of Florida, Texas, Arizona, California and North Carolina. The Company's goal is to maximize shareholder value by being a leading provider in its markets of functional, flexible and quality business distribution space for location sensitive customers (primarily in the 15,000 to 70,000 square foot range). The Company's strategy for growth is based on ownership of premier distribution facilities generally clustered near major transportation features in supply-constrained submarkets. EastGroup's portfolio, including development projects and value-add acquisitions in lease-up and under construction, currently includes approximately 45.7 million square feet.
Earnings Per Share
As for profitability, EastGroup Properties has a trailing twelve months EPS of $4.41.
PE Ratio
EastGroup Properties has a trailing twelve months price to earnings ratio of 42.2. Meaning, the purchaser of the share is investing $42.2 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.26%.
7. Ares Capital (ARCC)
9.9% sales growth and 12.67% return on equity
Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.
Earnings Per Share
As for profitability, Ares Capital has a trailing twelve months EPS of $2.68.
PE Ratio
Ares Capital has a trailing twelve months price to earnings ratio of 7.48. Meaning, the purchaser of the share is investing $7.48 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.67%.
Sales Growth
Ares Capital’s sales growth is 6% for the ongoing quarter and 9.9% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 22%, now sitting on 2.55B for the twelve trailing months.
Volume
Today’s last reported volume for Ares Capital is 2676820 which is 28.46% below its average volume of 3741790.
8. Huron Consulting Group (HURN)
8.7% sales growth and 13.83% return on equity
Huron Consulting Group Inc., a professional services firm, provides consultancy services in the United States and internationally. It operates through three segments: Healthcare, Education, and Commercial. The Healthcare segment provides advisory services in the areas of financial and operational improvement, care transformation, and revenue cycle managed services; organizational transformation; financial advisory; software products; and digital solutions, spanning technology and analytic-related services to national and regional health systems, academic and community health systems, public, children's and critical access hospitals, physician practices and medical groups, payors, and long-term care or post-acute providers. The Education segment provides research enterprise, and student and alumni lifecycle; digital solutions, spanning technology, and analytic-related services; Huron Research Suite, a software suite designed to facilitate and enhance research administration service delivery and compliance; and organizational transformation services to public and private colleges and universities, research institutes, and other education-related organizations. The Commercial segment delivers digital services and software products, and financial advisory services to financial, energy and utilities, professional and business services, life science, consumer products, and industrials and manufacturing industries, as well as public sector and nonprofit organizations. The company was incorporated in 2002 and is headquartered in Chicago, Illinois.
Earnings Per Share
As for profitability, Huron Consulting Group has a trailing twelve months EPS of $3.89.
PE Ratio
Huron Consulting Group has a trailing twelve months price to earnings ratio of 27.27. Meaning, the purchaser of the share is investing $27.27 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.83%.
